• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

    2/1/22 12:39:43 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    SC 13G/A 1 equillium13ga3_123121.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    ( Amendment No. 3)*

    Equillium, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    29446K106

    (CUSIP Number) 

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

             
    CUSIP No. 29446K106   13G   Page 2 of 4 Pages
             

     

             
    1.  

    NAMES OF REPORTING PERSONS

     

    Victory Capital Management Inc.


    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    13-2700161

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
       

     

             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

    SOLE VOTING POWER
     4,125,667

      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    4,125,667
      8.   SHARED DISPOSITIVE POWER
     
    0

     

             
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,125,667
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    14.04%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
             
             
                     
     
     

     

             
    CUSIP No. 29446K106   13G   Page 3 of 4 Pages
             

    Item 1.

      (a) Name of Issuer
    Equillium, Inc.
         
      (b)

    Address of Issuer’s Principal Executive Offices

    2223 Avenida De La Playa

    Suite 108

    La Jolla, CA 92037

         

    Item 2.

      (a) Name of Persons Filing
    Victory Capital Management Inc.
         
      (b)

    Address of the Principal Office or, if none, residence
    4900 Tiedeman Rd. 4th Floor

    Brooklyn, OH 44144

         
      (c) Citizenship
    New York
         
      (d) Title of Class of Securities
    Common Stock
         
      (e) CUSIP Number
    29446K106
         

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

     
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

             
      (a)   Amount beneficially owned:  4,125,667
             
      (b)   Percent of class:  14.04%
             
      (c)   Number of shares as to which the person has:
             
          (i)

    Sole power to vote or to direct the vote: 4,125,667

             
          (ii) Shared power to vote or to direct the vote:  0
             
          (iii) Sole power to dispose or to direct the disposition of:  4,125,667
             
          (iv)

    Shared power to dispose or to direct the disposition of:  0

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

             

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ¨

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    The clients of Victory Capital Management Inc., including investment companies registered under the Investment Company Act of 1940 and separately managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the class of securities reported herein. No client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of such class except the Victory RS Growth Fund which held 5.37%.

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     Not applicable

    Item 8.  Identification and Classification of Members of the Group.

     Not applicable.

    Item 9.  Notice of Dissolution of Group.

     Not applicable.

    Item 10.  Certification.

           
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
             
     
     

     

             
    CUSIP No. 29446K106   13G   Page 4 of 4 Pages
             

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    2/1/20212

    Date

     

    /s/ Colin S. Kinney

    Signature

     

    Colin S. Kinney / Chief Compliance Officer

    Name/Title

     

     

    Get the next $EQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Equillium downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously

      3/28/25 8:14:37 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Equillium with a new price target

      SVB Leerink reiterated coverage of Equillium with a rating of Outperform and set a new price target of $14.00 from $18.00 previously

      1/5/22 6:36:04 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Equillium with a new price target

      Stifel resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00

      10/29/21 8:33:13 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

      EQ504 protects against gut damage in a mouse model of ulcerative colitis EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7. "Decades of independent re

      5/6/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

      EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other immuno-inflammatory therapeutics EQ504 data to be presented in three poster presentations next week at the annual meeting of the American Association of Immunologists (AAI) Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor

      5/1/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces Feedback from the U.S. Food and Drug Administration

      Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for Accelerated Approval, as well as the company's filing for Breakthrough Therapy designation for itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data. The FDA highlighted

      4/24/25 9:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Colabuono Peter

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:50:43 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Demski Martha J

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:47:55 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pruzanski Mark

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:45:29 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    SEC Filings

    See more
    • Equillium Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Equillium, Inc. (0001746466) (Filer)

      6/13/25 4:05:42 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Equillium Inc.

      144 - Equillium, Inc. (0001746466) (Subject)

      6/12/25 4:19:18 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Equillium, Inc. (0001746466) (Filer)

      5/22/25 5:15:05 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Financials

    Live finance-specific insights

    See more
    • Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

      Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

      3/27/25 7:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Maintains Rights to Itolizumab Following Ono Partnership

      Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

      10/31/24 7:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

      Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

      12/6/22 7:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care